AMENDMENT TRANSMITS L LETTER (Small Entity) Applicant(s): Fossel, Eric T. AUG 2 4 1998						
		ng Date Ser 17, 1997	Examiner Mullis, J.			Group Art Unit 1711
Invention: TOPICAL DELIVERY OF L-ARGININE TO CAUSE BENEFICIAL EFFECTS						
🖾 Small En	TO THE with is an amendment attity status of this applically submitted.		tified applicat	ion.		verified statement
☐ A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed. The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR		ER EXTRA PRESENT	RATE	ADDITIONAL
TOTAL CLAIMS	28 -	32 =		0	x \$1	1.00 \$0.00
INDEP. CLAIMS	3 -	3 =		0	x \$4	1.00 \$0.00
Multiple Dependent Claims (check if applicable)						
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT \$0.00						
Please classe classe classe classe classe classes and a check in the Communication of the Com	Street	No. to cover the thorized to charge erpayment to Dependenced. equired under 37 C	e filing fee is e payment of cosit Account C.F.R. 1.16.	I certify that August 21, 19 class mail un Assistant Co	this docum 1998 Inder 37 C.I 10 mmissioner	nent and fee is being deposited of
Shelby J. Walker						

CC:

Typed or Printed Name of Person Mailing Correspondence



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

Mullis, J.

Serial No.:

08/932,227

FOSSEL, Eric

Art Unit:

1711

Title:

TOPICAL DELIVERY OF L-ARGININE TO CAUSE BENEFICIAL

EFFECTS

Filed:

September 17, 1997

Docket No.: FOS-104

Commissioner of Patents and Trademarks Washington, D.C. 20231

AMENDMENT AND RESPONSE

Sir:

This is applicant's response to the Office Action mailed March 23, 1998. The three month shortened statutory period for responding expired June 23, 1998. Accordingly, a petition and the fee for a two month extension under 37 C.F.R. §1.136(a) is filed herewith. Please amend the application as follows:

In the Claims

Cancel claims

Add the following claims:

A method of delivering a nitric oxide releasing substance selected from a member of the group consisting of L-arginine, L-arginine salts and L-arginine derivatives, to skin comprising the step of topically applying to the skin a vehicle containing an effective amount of the substance, and a concentration of ionic